OpenAlex
PricingAboutJobs
Log inGet started
Work

Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial

HTML

Year: 2011
Type: article
Study design: Clinical Trial
Source: Transplantation
DOI: 10.1097/tp.0b013e3182247ae2
Authors: Josefina Alberú, Michael D. Pascoe, Josep M. Campistol, Francesco P. Schena, Maria del Carmen Rial, Martin Polinsky, John F. Neylan, Joan Korth-Bradley, Robert Goldberg-Alberts, Eric S. Maller
Institutions: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, University of Cape Town, Groote Schuur Hospital, Hospital Clínic de Barcelona, University of Bari Aldo Moro, Quark Pharmaceuticals (United States), Wyeth, Pfizer (United States)
Language: English

Topic: Renal Transplantation Outcomes and Treatments
Subfield: Transplantation
Field: Medicine
Domain: Health Sciences
Keywords: rapamycin, calcineurin inhibitor-free immunosuppression, kidney transplant recipients, post-transplant malignancy, immunosuppression conversion, CONVERT trial, calcineurin inhibitors, skin cancer risk
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2333126124
FWCI: 15.9
Cites: 50
Cited by: 239
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms